Meeder Asset Management Inc. Purchases New Stake in Inogen, Inc. (NASDAQ:INGN)

Meeder Asset Management Inc. acquired a new position in Inogen, Inc. (NASDAQ:INGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,107 shares of the medical technology company’s stock, valued at approximately $56,000.

A number of other hedge funds have also recently added to or reduced their stakes in INGN. BNP Paribas Financial Markets lifted its position in shares of Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after buying an additional 5,131 shares during the last quarter. Verition Fund Management LLC bought a new position in Inogen in the third quarter worth about $106,000. Paloma Partners Management Co bought a new position in Inogen in the third quarter worth about $126,000. Centiva Capital LP acquired a new position in Inogen in the third quarter valued at approximately $138,000. Finally, Quarry LP bought a new position in shares of Inogen during the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Analysts Set New Price Targets

INGN has been the subject of a number of analyst reports. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, February 26th.

Inogen Stock Down 2.5 %

Shares of NASDAQ INGN opened at $6.95 on Wednesday. The stock has a market cap of $186.86 million, a P/E ratio of -3.09 and a beta of 1.16. The firm’s 50-day simple moving average is $9.25 and its 200 day simple moving average is $9.46. Inogen, Inc. has a fifty-two week low of $6.14 and a fifty-two week high of $13.33.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.